Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-13812 Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Low-Intermediate Risk Prostate Cancer III Radiation Therapy, Proton Therapy Not Applicable
CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma III Angiogenesis Inhibitor, Chemotherapy, Immunotherapy (Monoclonal Antibody) cisplatin; gemcitabine; bevacizumab
UPCC-22812 Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy II / III Radiation Therapy, Proton Therapy Not Applicable
UPCC-24213 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies I / II Chemotherapy, Signal Transduction Inhibitor paclitaxel; BBI608
UPCC-06810 Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy I Radiotherapy, Signal Transduction Inhibitor everolimus
3475-028 Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors I Immunotherapy, Signal Transduction Inhibitor MK-3475 (Immunotherapy : PD-1 inhibitor)
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC-13213 A Phase 1B Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors I Chemotherapy gemcitabine; nab-paclitaxel; INCB039110
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
UPCC-08809 A Trial of Proton Radiation Therapy Using Standard Fractionation for Low and Low-Intermediate Risk Adenocarcinoma of the Prostate Not Specified Proton Therapy Not Applicable
UPCC-18809 A Trial of Proton Radiation Therapy Using Mild Hypofractionation for Low and Intermediate Risk Adenocarcinoma of the Prostate Not Specified Radiation Therapy, Proton Therapy Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
AT005230 Rhodiola Rosea Therapy of Major Depressive Disorder III Supportive Care Not Applicable
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
UPCC-11111 A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in Relieving Persistent Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy. III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
CDR0000728901 Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate I Imaging Procedure Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CLDE225A2112 A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors I Other warfarin; bupropion
UPCC-07913 A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors I Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; paclitaxel; MLN4924
UPCC-05511 A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer I Immunotherapy MGA271
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-13812 Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Low-Intermediate Risk Prostate Cancer III Radiation Therapy, Proton Therapy Not Applicable
UPCC-22812 Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy II / III Radiation Therapy, Proton Therapy Not Applicable
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
UPCC-08809 A Trial of Proton Radiation Therapy Using Standard Fractionation for Low and Low-Intermediate Risk Adenocarcinoma of the Prostate Not Specified Proton Therapy Not Applicable
UPCC-18809 A Trial of Proton Radiation Therapy Using Mild Hypofractionation for Low and Intermediate Risk Adenocarcinoma of the Prostate Not Specified Radiation Therapy, Proton Therapy Not Applicable